# Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

Source: https://onco.cc/trials/nct03907852/  
OnCo record `nct03907852` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Fludarabine, Cyclophosphamide, Nivolumab in mesothelioma and ovarian cancer, run by TCR2 Therapeutics, active and no longer recruiting.

## Summary

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer is a phase 1/2 interventional study registered as NCT03907852 by TCR2 Therapeutics, with 57 participants enrolled, started 2019-04-15 and due to reach its primary completion in 2024-11-19. Interventions recorded: gavo-cel, fludarabine, cyclophosphamide, Nivolumab, Ipilimumab. Conditions listed: Mesothelioma, Mesothelioma, Malignant, Mesothelioma; Pleura, Mesotheliomas Pleural. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT03907852
- Phase: 1/2
- Setting: A Phase 1/2 Single Arm Open-Label Clinical Trial of Gavocabtagene Autoleucel (Gavo-cel) in Patients With Advanced Mesothelin-Expressing Cancer
- Sponsor: TCR2 Therapeutics
- Enrolled: 57

## Sources

- ClinicalTrials.gov NCT03907852: https://clinicaltrials.gov/study/NCT03907852

## Connected records

- cancers: [Mesothelioma](https://onco.cc/cancers/mesothelioma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Fludarabine](https://onco.cc/drugs/fludarabine/), [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/)

---
JSON: https://onco.cc/api/v1/entities/nct03907852.json